January 2026 in “British Journal of Clinical Pharmacology” Serenoa repens may cause long-lasting sexual and psychiatric side effects.
January 2026 in “EJC Skin Cancer” The serum effectively improves hair growth and is well-tolerated for post-cancer hair loss.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” Pharmacists should lead discussions on finasteride's safety due to its link to suicidal thoughts.
December 2025 in “Cureus” Post-COVID syndrome symptoms are common and overlap with general health issues.
December 2025 in “Cosmetics” Nanocarriers can improve skin treatments after cancer therapy by enhancing antioxidant delivery and effectiveness.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Post-drug syndromes are often overlooked, and better systems and education are needed to improve drug safety.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Current drug safety systems fail to detect long-term side effects, needing improvements to protect health and trust.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Current drug safety systems fail to detect long-term side effects, leading to preventable health issues.
November 2025 in “Journal of Disease and Public Health” Post-COVID-19 syndrome is complex, affects 5%-10% of people, and requires better research and global collaboration for treatment.
October 2025 in “Journal of Pharmacy And Bioallied Sciences” Post-COVID, many patients experience skin issues like hair loss and herpes reactivation, especially in middle-aged women.
October 2025 in “Cermin Dunia Kedokteran” Proper management of PTSD with psychotherapy and medication can reduce symptoms.
September 2025 in “Journal of the American Academy of Dermatology” Vitiligo may be linked to stopping finasteride.
August 2025 in “International Journal of Clinical Dermatology” A new skin cancer can develop where shingles once occurred.
August 2025 in “مجلة جامعة الحضارة للبحوث التطبيقية والإنسانية” Tissue expansion effectively corrects post-burn and traumatic scars with high patient satisfaction and low complications.
COVID-19 can trigger a relapsing form of hair loss, requiring long-term treatment strategies.
Allopregnanolone may help reduce inflammation and symptoms related to post-finasteride syndrome.
May 2025 in “Journal of Cosmetic Dermatology” Post-finasteride syndrome may be linked to pre-existing psychological issues, not just the drug.
February 2025 in “International Journal of Impotence Research”
January 2025 in “Dermatology Practical & Conceptual” Anemia increases the risk of hair loss in post-COVID-19 survivors.
October 2024 in “Journal of the Endocrine Society” Post-finasteride syndrome can cause lasting sexual, physical, and mental health issues with limited treatment options.
September 2024 in “Electronic Journal of General Medicine” Laser hair removal can cause severe skin irritation, but it can improve with treatment.
September 2024 in “Journal of the American Academy of Dermatology” Subcision is the most efficient, cost-effective, and safest treatment for post-acne boxcar scarring in skin of color.
August 2024 in “International Journal of Nursing Studies Advances” Following hair transplant surgery, proper self-care is crucial for successful recovery and hair growth.
August 2024 in “Journal of Small Animal Practice” A cat lost hair on its back a month after a road accident, despite no initial skin injuries.
July 2024 in “Vestnik dermatologii i venerologii” Post-COVID-19 hair loss is different from androgenetic alopecia and can be identified by lower copper and higher selenium levels.
June 2024 in “Trends in Urology & Men s Health” Post-finasteride syndrome is rare but serious and should be taken seriously.
June 2024 in “International journal of impotence research” The author had undisclosed conflicts of interest related to the original article on post-finasteride syndrome.
Post-COVID-19 hair loss is not linked to vitamin D or quality of life but is linked to hair graying.
Finasteride may cause memory problems by damaging the hippocampus.
Finasteride may cause changes in dopamine-related genes, possibly leading to post-finasteride syndrome.